VBI Vaccines Inc., a biopharmaceutical company based in Cambridge, Massachusetts, is making strides in the development of vaccines to combat immuno-oncology and infectious diseases. Among its offerings is Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company is also working on VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection, and VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, currently in Phase I/IIa clinical study to treat solid tumors. In addition, VBI Vaccines Inc. has completed Phase I clinical trials of VBI-1501, a prophylactic cytomegalovirus vaccine candidate and is continuing its preclinical trial of VBI-2501 in order to treat the Zika virus. The company has been working on several coronavirus vaccine candidates, including VBI-2902, VBI-2901, and VBI-2905. VBI Vaccines Inc. has also entered into collaboration and license agreements with Brii Biosciences Limited, GlaxoSmithKline Biologicals S.A., and the National Research Council of Canada to create a pan-coronavirus vaccine candidate. This candidate could potentially target COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. Additionally, the company is working with the Coalition for Epidemic Preparedness Innovations to advance vaccine candidates that can address COVID-19 variants. Formerly known as SciVac Therapeutics Inc., VBI Vaccines Inc. changed its name in May 2016. The company's impressive efforts in the world of biopharmaceuticals are worth watching.